Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Extension of Convertible Note Maturity Date, Vista Capital [Member] Common Stock [Member]	Extension of Convertible Note Maturity Date, Vista Capital [Member] Additional Paid-in Capital [Member]	Extension of Convertible Note Maturity Date, Vista Capital [Member] Retained Earnings [Member]	Extension of Convertible Note Maturity Date, Vista Capital [Member] AOCI Attributable to Parent [Member]	Extension of Convertible Note Maturity Date, Vista Capital [Member] Noncontrolling Interest [Member]	Extension of Convertible Note Maturity Date, Vista Capital [Member]	Clyra Medical Technology Inc [Member] Common Stock [Member]	Clyra Medical Technology Inc [Member] Additional Paid-in Capital [Member]	Clyra Medical Technology Inc [Member] Retained Earnings [Member]	Clyra Medical Technology Inc [Member] AOCI Attributable to Parent [Member]	Clyra Medical Technology Inc [Member] Noncontrolling Interest [Member]	Clyra Medical Technology Inc [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2018													141,466,071
Balance at Dec. 31, 2018													$ 95,000	$ 110,222,000	$ (111,723,000)	$ (90,000)	$ 373,000	$ (1,123,000)
Conversion of notes (in shares)													1,638,479
Conversion of notes													$ 1,000	218,000				219,000
Issuance of common stock for service (in shares)													1,229,541
Issuance of common stock for service													$ 1,000	205,000				206,000
Issuance of common stock for interest (in shares)													139,362
Issuance of common stock for interest														25,000				25,000
Stock option compensation expense														352,000				352,000
Warrants and conversion feature issued as discount on convertible notes payable and line of credit														1,115,000				1,115,000
Fair value of warrants for extension of debt		$ 56,000				$ 56,000
Deemed dividend for the change in accounting for derivative liability														342,000	(342,000)
Clyra Medical securities offering														21,000			89,000	110,000
Net loss															(2,576,000)		(173,000)	(2,749,000)
Foreign currency translation																(4,000)		(4,000)
Balance (in shares) at Mar. 31, 2019													144,473,453
Balance at Mar. 31, 2019													$ 97,000	112,556,000	(114,641,000)	(94,000)	289,000	(1,793,000)
Balance (in shares) at Dec. 31, 2019													166,256,024
Balance at Dec. 31, 2019													$ 111,000	121,327,000	(123,492,000)	(99,000)	(27,000)	(2,180,000)
Conversion of notes (in shares)													3,387,649
Conversion of notes													$ 2,000	432,000				434,000
Issuance of common stock for service (in shares)													1,039,490
Issuance of common stock for service													$ 1,000	177,000				178,000
Issuance of common stock for interest (in shares)													19,278
Issuance of common stock for interest														4,000				4,000
Stock option compensation expense								$ 420,000				$ 420,000		320,000				320,000
Deemed dividend for the change in accounting for derivative liability														100,000	(100,000)
Clyra Medical securities offering														15,000				25,000
Net loss															(2,274,000)		(342,000)	(2,616,000)
Foreign currency translation
Sale of common stock for cash (in shares)													4,848,305
Sale of common stock for cash													$ 3,000	898,000				901,000
Common stock issued as a financing fee; deferred offering costs (in shares)													2,928,571
Common stock issued as a financing fee; deferred offering costs													$ 2,000	(124,000)				(122,000)
Clyra Medical securities offering																	10,000
Allocation of noncontrolling interest from Clyra Stock option issuance														(448,000)			448,000
Balance (in shares) at Mar. 31, 2020													178,479,317
Balance at Mar. 31, 2020													$ 119,000	$ 123,121,000	$ (125,866,000)	$ (99,000)	$ 89,000	$ (2,636,000)